Summary: The Centers for Medicare & Medicaid Services modified its photosensitive drugs coverage policy, effective May 15, 2026. Here's what billing teams need to know before that date.
CMS photosensitive drug coverage policy changes don't happen often, but when they do, they hit revenue cycle teams hard and fast. This modification affects how Medicare-covered photosensitizing agents and photodynamic therapy are billed, documented, and authorized. The policy does not carry a numbered policy code in CMS's standard numbering system. The specific codes this policy governs are not listed in the current published policy document — more on what that means for your billing team below.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Centers for Medicare & Medicaid Services (CMS) |
| Policy | Photosensitive Drugs |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium-High |
| Specialties Affected | Oncology, Dermatology, Ophthalmology, Gastroenterology |
| Key Action | Review photosensitive drug billing documentation and prior authorization workflows before May 15, 2026 |
CMS Photosensitive Drugs Coverage Criteria and Medical Necessity Requirements 2026
Photosensitive drugs — also called photosensitizing agents — are drugs used in photodynamic therapy (PDT). They make tissue sensitive to specific wavelengths of light. When activated by light, these drugs destroy targeted cells. CMS coverage of these agents has always been tied tightly to medical necessity criteria, and this 2026 modification continues that pattern.
Medicare's general position on photosensitive drug coverage is that reimbursement depends on the drug, the indication, the delivery route, and whether the procedure pairing is itself covered. A drug is rarely covered in isolation. CMS evaluates the photosensitizer and the light activation together as a treatment system.
Medical necessity documentation for photosensitive drugs under Medicare requires a confirmed diagnosis, a documented treatment plan, and evidence that alternative therapies were considered or attempted. "Medical necessity" here is not a formality. CMS auditors look at whether the clinical record supports the specific indication for which the drug was used. Vague documentation — "patient tolerated procedure well" — does not satisfy this standard.
Whether photosensitive drug billing requires prior authorization depends on the specific agent, the setting, and your Medicare Administrative Contractor's regional policies. Some MACs have issued local coverage determinations that layer additional requirements on top of the national policy. Check your MAC's LCD portal before assuming the national policy is the only requirement in play.
The real issue with this coverage policy modification is what it does to your documentation workflow. If your oncology or dermatology billing team has been running PDT billing on auto-pilot, this is the moment to audit that process. A modified policy — even one that seems incremental — resets the compliance clock.
CMS Photosensitive Drugs Exclusions and Non-Covered Indications
Medicare does not cover photosensitive drugs used for cosmetic indications. If the treatment goal is aesthetic improvement rather than treatment of a confirmed diagnosis, CMS will deny the claim.
Experimental or investigational use of photosensitizing agents is also excluded. If a drug is being used off-label for an indication not supported by peer-reviewed clinical evidence or CMS coverage guidance, expect a claim denial. CMS follows the evidence closely on this category of drug, and off-label PDT billing is a known audit trigger.
Compounded photosensitizing agents present additional risk. Medicare does not reimburse compounded drugs the same way it reimburses FDA-approved formulations. If your practice uses a compounded version of a covered photosensitizer, confirm separately that your MAC has guidance allowing reimbursement before billing.
Coverage Indications at a Glance
Because the published policy document does not list specific codes or indication-level criteria, the table below reflects CMS's established general positions on photosensitive drug coverage categories. Confirm each indication against your MAC's local coverage determination.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Photodynamic therapy for actinic keratosis | Covered (when criteria met) | Not specified in policy data | Medical necessity documentation required |
| PDT for Barrett's esophagus with high-grade dysplasia | Covered (when criteria met) | Not specified in policy data | Confirm MAC LCD; prior authorization may apply |
| PDT for endobronchial non-small cell lung cancer | Covered (when criteria met) | Not specified in policy data | Specialist documentation required |
| PDT for age-related macular degeneration (AMD) | Covered for specific subtypes (when criteria met) | Not specified in policy data | Subtype and drug-specific; confirm current CMS guidance |
| Cosmetic PDT applications | Not Covered | N/A | No medical necessity basis under Medicare |
| Off-label or investigational photosensitizer use | Not Covered / Experimental | N/A | Claim denial risk is high |
| Compounded photosensitizing agents | Coverage varies by MAC | Not specified in policy data | Verify with your MAC before billing |
Note: The policy document does not list specific CPT, HCPCS, or ICD-10 codes. The indications above reflect CMS's established general coverage framework for photosensitive drugs. Do not treat this table as a substitute for your MAC's current LCD.
CMS Photosensitive Drugs Billing Guidelines and Action Items 2026
The modified coverage policy takes effect May 15, 2026. That gives billing teams a defined window to act. Here's what to do before that date.
| # | Action Item |
|---|---|
| 1 | Pull your MAC's current LCD for photodynamic therapy and photosensitizing agents. The national policy is the floor, not the ceiling. Your Medicare Administrative Contractor may have issued a local coverage determination with stricter criteria, additional diagnosis code requirements, or specific prior authorization rules. If you bill in multiple MAC jurisdictions, check each one. |
| 2 | Audit claims from the last 12 months for photosensitive drug billing. Look for patterns that could indicate documentation gaps — missing diagnosis codes, missing treatment plans, or drugs billed without a corresponding procedure. A claim denial after May 15, 2026 based on insufficient documentation is preventable right now. |
| 3 | Confirm your prior authorization workflow covers every photosensitizing agent your practice uses. Not every agent requires prior auth under every MAC, but the ones that do are high-dollar claims. A missed prior authorization on a photosensitive drug claim is not a minor billing error. It's a full denial. |
| 4 | Update your charge capture templates to flag photosensitive drug claims for documentation review. Build the review into the workflow, not as an afterthought before submission. Your billing team should not be the last line of defense on medical necessity documentation — that responsibility belongs in the clinical workflow. |
| 5 | Verify reimbursement rates for any photosensitizing agents on your formulary against the current CMS fee schedule. Drug reimbursement under Medicare Part B is calculated based on average sales price (ASP). If a drug's ASP changes in 2026, your expected reimbursement changes with it. This is separate from the coverage policy change, but it's worth checking at the same time. |
| 6 | Talk to your compliance officer before May 15, 2026 if your practice uses photosensitizing agents in a setting or for an indication that isn't clearly addressed in your MAC's LCD. The gap between national policy and local determination is where audit risk lives. Don't guess. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Photosensitive Drugs Under This Policy
The published policy document for this CMS modification does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is not unusual for CMS policy documents that govern drug categories rather than individual procedures — but it does create a challenge for photosensitive drug billing teams who need code-level specificity.
Do not use codes found in third-party summaries or older versions of this policy without verifying them against the current CMS policy document and your MAC's LCD. Using outdated or assumed codes is one of the fastest ways to generate systematic claim denials under a modified policy.
Where to Find the Right Codes
Your MAC's LCD for photodynamic therapy is the right source for covered diagnosis codes and procedure codes. CMS's Drug Payment Table (updated quarterly) is the right source for HCPCS J-codes tied to specific photosensitizing agents. The CMS fee schedule lookup tool gives you current Part B reimbursement rates by HCPCS code.
If your coding team is unsure which codes apply to a specific photosensitizer your practice uses, that is a compliance question — not just a billing question. Loop in your compliance officer or a qualified billing consultant before the May 15, 2026 effective date.
What Billing Teams Typically Use for PDT (General Reference — Not From This Policy)
Because this policy does not list codes, the following reflects general industry knowledge about PDT billing. Confirm every code against your MAC's LCD and the current CMS fee schedule before using.
Photodynamic therapy procedures are typically billed with CPT codes in the destruction and dermatology procedure ranges, or with gastroenterology or pulmonology endoscopy codes depending on the site of service. Photosensitizing drugs administered in an outpatient or office setting are typically billed using HCPCS J-codes specific to each FDA-approved agent. ICD-10-CM codes vary by indication — actinic keratosis, Barrett's esophagus, AMD, and lung cancer each have distinct diagnosis code families.
Again: the policy document does not confirm specific codes. Treat the above as a starting point for your own verification, not as billing guidance.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.